Aliases & Classifications for Motion Sickness

Aliases & Descriptions for Motion Sickness:

Name: Motion Sickness 12 41 42 14 69
Travel Sickness 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2951
ICD10 33 T75.3
ICD9CM 35 994.6
MeSH 42 D009041
NCIt 47 C34824
UMLS 69 C0026603

Summaries for Motion Sickness

MedlinePlus : 41 motion sickness is a common problem in people traveling by car, train, airplanes, and especially boats. anyone can get it, but it is more common in children, pregnant women, and people taking certain medicines. motion sickness can start suddenly, with a queasy feeling and cold sweats. it can then lead to dizziness and nausea and vomiting. your brain senses movement by getting signals from your inner ears, eyes, muscles, and joints. when it gets signals that do not match, you can get motion sickness. for example, if you are reading on your phone while riding a bus, your eyes are focused on something that is not moving, but your inner ear senses motion. where you sit can make a difference. the front seat of a car, forward cars of a train, upper deck on a boat or wing seats in a plane may give you a smoother ride. looking out into the distance - instead of trying to read or look at something in the vehicle - can also help. centers for disease control and prevention

MalaCards based summary : Motion Sickness, also known as travel sickness, is related to space motion sickness and anodontia, and has symptoms including abnormality of the nervous system, abdominal pain and asthenia. An important gene associated with Motion Sickness is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Monoamine GPCRs and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Dexmedetomidine and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and skin, and related phenotypes are Increased transferrin (TF) endocytosis and behavior/neurological

Wikipedia : 71 Motion sickness, also known as kinetosis and travel sickness, is a condition in which a disagreement... more...

Related Diseases for Motion Sickness

Diseases related to Motion Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
id Related Disease Score Top Affiliating Genes
1 space motion sickness 12.3
2 anodontia 10.2 HTR1A HTR3A
3 prediabetes syndrome 10.2 AQP1 AVP
4 lateral sinus thrombosis 10.2 AVP HTR3A
5 dry eye syndrome 10.2 HTR1A HTR7
6 scleral staphyloma 10.1 HTR3A HTR7
7 abnormal pupillary function 10.1 HTR1A HTR3A HTR7
8 renpenning syndrome 10.1 HTR1A HTR3A HTR7
9 tinea pedis 10.1 HTR1A HTR7
10 intestinal disaccharidase deficiency 10.1 AVP FAM136A
11 luxation of globe 10.1 HTR1A HTR7
12 neuronitis 10.0
13 urethral gland abscess 10.0 AQP1 FAM136A
14 laryngitis 10.0 AQP1 AVP FAM136A
15 hepatitis b reinfection following liver transplantation 10.0 HTR1A HTR3A TAC1
16 deafness, autosomal recessive 20 10.0 HTR3A HTR7 TAC1
17 gnathomiasis 10.0 HTR3A HTR7 TAC1
18 tuberculous peritonitis 9.9 HTR3A HTR7 TAC1
19 autoimmune disease of endocrine system 9.9 FOS HTR7
20 atrial fibrillation, familial, 10 9.9 FOS HTR1A HTR3A
21 allergic hypersensitivity disease 9.9 FOS HTR1A HTR7
22 vascular cancer 9.9 FOS HTR1A HTR7
23 microcephaly 13, primary, autosomal recessive 9.8 HTR1A HTR3A HTR7 TAC1
24 preeclampsia/eclampsia 5 9.8 HTR1A HTR3A HTR7
25 adult brain stem glioma 9.8 AVP CHIT1 FOS
26 syncope 9.8
27 scoliosis 9.8
28 idiopathic scoliosis 9.8
29 yaws 9.8
30 siberian tick typhus 9.8 FOS HTR1A HTR3A HTR7
31 ellis-van creveld syndrome 9.7 ADRA2A FOS HTR1A
32 cervical carcinosarcoma 9.7 FOS HTR7 TAC1
33 hyperglycemia 9.7
34 retinal degeneration 9.7
35 mal de debarquement 9.7
36 ataxia 9.7
37 headache 9.7
38 hypoxia 9.7
39 orthostatic intolerance 9.7
40 spinal cord injury 9.7
41 thrombosis 9.7
42 cervicitis 9.7
43 retinitis 9.7
44 personality disorder 9.6 FOS HTR1A HTR7 TAC1
45 mixed lacrimal gland cancer 8.6 ADRA2A AQP1 AVP CHIT1 EXT2 FAM136A

Graphical network of the top 20 diseases related to Motion Sickness:



Diseases related to Motion Sickness

Symptoms & Phenotypes for Motion Sickness

Human phenotypes related to Motion Sickness:

32
id Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 32 HP:0000707

UMLS symptoms related to Motion Sickness:


abdominal pain, asthenia, body temperature changes, chest pain, constipation, coughing, cyanosis, diarrhea, dyspepsia, edema, eye manifestations, fatigue, fever, flushing, halitosis, headache, heartburn, icterus, nausea and vomiting, oral manifestations, pain, pelvic pain, pruritus, sciatica, signs and symptoms, signs and symptoms, digestive, signs and symptoms, respiratory, skin manifestations, syncope, vertigo, chills, polydipsia, chronic pain, renal colic, vertigo/dizziness, gastrointestinal gas, hot flushes, urological manifestations, symptoms, mobility limitation, prodromal symptoms, hypertriglyceridemic waist, medically unexplained symptoms

GenomeRNAi Phenotypes related to Motion Sickness according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.23 ADRA2A AVP CHIT1 FOS HTR1A HTR3A

MGI Mouse Phenotypes related to Motion Sickness:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.76 ADRA2A AQP1 AVP FOS HTR1A HTR3A
2 mortality/aging MP:0010768 9.56 ADRA2A AQP1 AVP EXT2 FOS HTR1A
3 nervous system MP:0003631 9.17 ADRA2A AQP1 AVP FOS HTR1A HTR3A

Drugs & Therapeutics for Motion Sickness

Drugs for Motion Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Ondansetron Approved Phase 4 99614-02-5 4595
6
Diphenhydramine Approved Phase 4 58-73-1, 147-24-0 3100
7
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
8
Promethazine Approved Phase 4 60-87-7 4927
9
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
10
Fosaprepitant Approved Phase 4 172673-20-0 219090
11
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
12
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
13
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
14
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
15
Substance P Investigational Phase 4 33507-63-0 44359816
16 Adjuvants, Anesthesia Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
17 Adrenergic Agents Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic alpha-2 Receptor Agonists Phase 4
20 Adrenergic alpha-Agonists Phase 4
21 Analgesics Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Analgesics, Opioid Phase 4
24 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
25 Anesthetics, General Phase 4
26 Anesthetics, Intravenous Phase 4
27 Anti-Anxiety Agents Phase 4
28 Central Nervous System Depressants Phase 4,Phase 2
29 GABA Agents Phase 4
30 GABA Modulators Phase 4
31 Hypnotics and Sedatives Phase 4,Phase 2
32 Narcotics Phase 4
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Psychotropic Drugs Phase 4,Phase 1
36 Tranquilizing Agents Phase 4
37 Antiemetics Phase 4,Phase 2
38 Antipruritics Phase 4
39 Antipsychotic Agents Phase 4
40 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Dermatologic Agents Phase 4
42 Gastrointestinal Agents Phase 4,Phase 2
43
Serotonin Phase 4,Phase 1 50-67-9 5202
44 Serotonin Agents Phase 4,Phase 1
45 Serotonin Antagonists Phase 4
46 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Anesthetics, Local Phase 4
48 Anti-Allergic Agents Phase 4,Phase 2
49 Histamine Antagonists Phase 4,Phase 2
50 Histamine H1 Antagonists Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 104)
id Name Status NCT ID Phase
1 Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU) Unknown status NCT01059929 Phase 4
2 The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting Completed NCT01897337 Phase 4
3 Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting. Completed NCT02286752 Phase 4
4 Brace Versus Casting in Pediatric Low Risk Ankle Fractures Completed NCT00132964 Phase 4
5 Cast Versus Splint in Children With Acceptably Angulated Wrist Fractures Completed NCT00610220 Phase 4
6 A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects Recruiting NCT02802514 Phase 4
7 Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Recruiting NCT02455622 Phase 4
8 Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels Suspended NCT02136420 Phase 4
9 The Effect of Gum Chewing on Postoperative Ileus Unknown status NCT00879294 Phase 3
10 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
11 Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Completed NCT00630747 Phase 2, Phase 3
12 Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients Completed NCT00146770 Phase 3
13 Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery Completed NCT00412035 Phase 3
14 Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) Completed NCT00069641 Phase 2, Phase 3
15 Remote Ischemic Preconditioning in Primary PCI Completed NCT00435266 Phase 2, Phase 3
16 Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray Terminated NCT02155309 Phase 2, Phase 3
17 Electroacupuncture for Chronic Neck Pain Unknown status NCT00826215 Phase 2
18 Levo Phencynonate Hydrochloride for the Prevention of Seasickness Completed NCT02241629 Phase 2
19 Effects of Transdermal Scopolamine on Occupational Performance Completed NCT00374478 Phase 2
20 Meclizine as a Potential Smoking Cessation Treatment Completed NCT01443858 Phase 2
21 Phase II Dose-ranging Study of APD421 in PONV Completed NCT01510704 Phase 2
22 Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV) Completed NCT00895830 Phase 2
23 Early Directed Physical Therapy in the Management of Mechanically Ventilated Patients in a Medical Intensive Care Unit Completed NCT00322010 Phase 2
24 Effect of Tai Chi Vs. Structured Exercise on Physical Fitness and Stress in Cancer Survivors Completed NCT00246818 Phase 2
25 PEAK Study (Physical Exercise and Activity in Kids) Completed NCT00213187 Phase 2
26 A Pilot Study on Exercise After Achilles Tendon Rupture Completed NCT01298024 Phase 2
27 Promotion of Oesophageal Motility to Prevent Regurgitation and Enhance Nutrition Intake in ICU Patients. Recruiting NCT02515123 Phase 2
28 CYCLE Pilot Randomized Trial Recruiting NCT02377830 Phase 2
29 Metal-metal Articulations Versus Standard 28 mm Cementless Total Hip Arthroplasty Active, not recruiting NCT01113762 Phase 2
30 Melatonin for Prevention of Delirium in Critically Ill Patients Not yet recruiting NCT02615340 Phase 2
31 A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. Completed NCT02839135 Phase 1
32 Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness Completed NCT01669304 Phase 1
33 Assessing Deformable Image Registration in the Lung Using Hyperpolarized-gas MRI Recruiting NCT02995590 Phase 1
34 A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness Unknown status NCT01198106
35 Rescue Emetic Therapy for Children Having Elective Surgery Unknown status NCT01067677
36 Effect of Combined Exercise Post-treatment Intervention in Lean Mass Recovery in Breast Cancer Survival. Unknown status NCT01843608
37 Trial for the Treatment of Pelvic and Back Pain in Pregnancy Unknown status NCT00830934
38 Transcultural Multidisciplinary Evaluation of Patients With Hemophili Unknown status NCT02199639
39 Neuroscience Education on Osteoarthritis Unknown status NCT02246088
40 Burden of Shoulder Disorders in Primary Health Care Unknown status NCT01300091
41 Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? Completed NCT00360282
42 Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy Volunteers Completed NCT02177890
43 Study of Hierarchy of Afferents in Postural Control of Children With Dyslexia Completed NCT02879786
44 Risk Factors for Post Operative Nausea and Vomiting(PONV) in Patients Underwent Gynecological Operation Under General Anesthesia Completed NCT01020201
45 Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI Completed NCT01379001
46 Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia Completed NCT02416115
47 Virtual Reality Distraction for Procedural Pain Management and Anxiety in Children With Burn Injuries : A Pilot Study Completed NCT02794103
48 Dose of Early Therapeutic Mobility: Does Type or Frequency Matter? Completed NCT00999011
49 Endotoxin-induced Inflammatory and Behavioral Responses and Predictors of Individual Differences Completed NCT02529592
50 The Effects of the Anesthetic Ketamine in Young Children Undergoing Procedural Sedation Completed NCT02650154

Search NIH Clinical Center for Motion Sickness

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: motion sickness

Genetic Tests for Motion Sickness

Anatomical Context for Motion Sickness

MalaCards organs/tissues related to Motion Sickness:

39
Eye, Brain, Skin, Testes, Heart, Amygdala, Hypothalamus

Publications for Motion Sickness

Articles related to Motion Sickness:

(show top 50) (show all 596)
id Title Authors Year
1
Prevalence, Predictors, and Prevention of Motion Sickness in Zero-G Parabolic Flights. ( 28061915 )
2017
2
The virtual reality head-mounted display Oculus Rift induces motion sickness and is sexist in its effects. ( 27915367 )
2016
3
Effects of naloxone on motion sickness in cats alone and with broad spectrum antiemetics. ( 27615675 )
2016
4
Biodynamic Hypothesis for the Frequency Tuning of Motion Sickness. ( 26735236 )
2016
5
The influence of sleep deprivation and oscillating motion on sleepiness, motion sickness, and cognitive and motor performance. ( 27641791 )
2016
6
Meniere's, migraine, and motion sickness. ( 27918236 )
2016
7
Motion sickness in ancient China: Seasickness and cart-sickness. ( 27432177 )
2016
8
Moving in a Moving World: A Review on Vestibular Motion Sickness. ( 26913019 )
2016
9
The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness. ( 27160425 )
2016
10
Subjective Vertical Conflict Theory and Space Motion Sickness. ( 26802378 )
2016
11
Motion Sickness and Resting Energy Expenditure in Chinese Male Adults. ( 27026119 )
2016
12
Vestibular evoked myogenic potentials and motion sickness medications. ( 27178852 )
2016
13
Psychometric Properties of the Greek Version of the Gianaros Motion Sickness Assessment Questionnaire. ( 27779955 )
2016
14
Motion sickness and sopite syndrome associated with parabolic flights: a case report. ( 26624575 )
2016
15
Evaluation of Motion Sickness Induced by 3D Video Clips. ( 26832611 )
2016
16
Motion Sickness Prediction in Aeromedical Evacuation of Patients with Ebola. ( 26735238 )
2016
17
Motion sickness. ( 27638085 )
2016
18
Contribution of intra-vestibular sensory conflict to motion sickness and dizziness in migraine disorders. ( 27385797 )
2016
19
EEG Alpha and Gamma Modulators Mediate Motion Sickness-Related Spectral Responses. ( 26790485 )
2016
20
Effect of passengers' active head tilt and opening/closure of eyes on motion sickness in lateral acceleration environment of cars. ( 26481809 )
2015
21
Visually induced motion sickness when viewing visual oscillations of different frequencies along the fore-and-aft axis: keeping velocity versus amplitude constant. ( 26280175 )
2015
22
Formulation of Eco-friendly Medicated Chewing Gum to Prevent Motion Sickness. ( 25652732 )
2015
23
Vection and visually induced motion sickness: how are they related? ( 25941509 )
2015
24
Motion Sickness: Current Knowledge and Recent Advance. ( 26452639 )
2015
25
Relationship between Spectral Characteristics of Spontaneous Postural Sway and Motion Sickness Susceptibility. ( 26657203 )
2015
26
Electrocortical therapy for motion sickness. ( 26341870 )
2015
27
Inter-hemispheric desynchronization of the human MT+ during visually induced motion sickness. ( 26014459 )
2015
28
Susceptibility to motion sickness is not increased following spinal cord injury. ( 25882475 )
2015
29
Prediction of Symptom Change in Placebo Versus No-Treatment Group in Experimentally Induced Motion Sickness. ( 25912825 )
2015
30
A Medical Food Formulation of Griffonia simplicifolia/Magnesium for Childhood Periodic Syndrome Therapy: An Open-Label Study on Motion Sickness. ( 25590358 )
2015
31
Pathophysiology and treatment of motion sickness. ( 25502048 )
2015
32
AVP modulation of the vestibular nucleus via V1b receptors potentially contributes to the development of motion sickness in rat. ( 26651338 )
2015
33
Sex differences in visual performance and postural sway precede sex differences in visually induced motion sickness. ( 26466829 )
2015
34
Motion sickness is associated with an increase in vestibular modulation of skin but not muscle sympathetic nerve activity. ( 26025612 )
2015
35
Using bio-signals to evaluate multi discomfort in image viewing - balancing visually induced motion sickness and field of view. ( 26737708 )
2015
36
Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. ( 25628336 )
2015
37
Visually induced motion sickness can be alleviated by pleasant odors. ( 25633319 )
2015
38
Visual blur and motion sickness in an optokinetic drum. ( 25945660 )
2015
39
EEG based time and frequency dynamics analysis of visually induced motion sickness (VIMS). ( 26462677 )
2015
40
Diaphragmatic breathing and its effectiveness for the management of motion sickness. ( 25945662 )
2015
41
Evaluation of motion sickness susceptibility by motion sickness susceptibility questionnaire in adolescents with idiopathic scoliosis: a case-control study. ( 26077100 )
2015
42
A Wearable Device Providing a Visual Fixation Point for the Alleviation of Motion Sickness Symptoms. ( 26633672 )
2015
43
Quantitative orientation preference and susceptibility to space motion sickness simulated in a virtual reality environment. ( 25647233 )
2015
44
Differential Gene Expression Profile in the Rat Caudal Vestibular Nucleus is Associated with Individual Differences in Motion Sickness Susceptibility. ( 25910039 )
2015
45
Sex Differences in the Incidence of Motion Sickness Induced by Linear Visual Oscillation. ( 26388085 )
2015
46
Three statistical experimental designs for enhancing yield of active compounds from herbal medicines and anti-motion sickness bioactivity. ( 26246716 )
2015
47
Microgravity Simulated by the 6A^ Head-Down Tilt Bed Rest Test Increases Intestinal Motility but Fails to Induce Gastrointestinal Symptoms of Space Motion Sickness. ( 26055239 )
2015
48
How to study placebo responses in motion sickness with a rotation chair paradigm in healthy participants. ( 25549015 )
2014
49
Motion sickness prevalence in school children. ( 24893949 )
2014
50
The comparison of sensitivity of motion sickness between retinal degeneration fast mice and normal mice. ( 24553916 )
2014

Variations for Motion Sickness

Expression for Motion Sickness

Search GEO for disease gene expression data for Motion Sickness.

Pathways for Motion Sickness

GO Terms for Motion Sickness

Cellular components related to Motion Sickness according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 8.8 AQP1 HTR3A TAC1

Biological processes related to Motion Sickness according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 sensory perception of pain GO:0019233 9.49 AQP1 TAC1
2 cellular response to hormone stimulus GO:0032870 9.48 ADRA2A FOS
3 positive regulation of epithelial cell migration GO:0010634 9.46 AQP1 TAC1
4 renal water homeostasis GO:0003091 9.43 AQP1 AVP
5 water transport GO:0006833 9.4 AQP1 AVP
6 multicellular organismal water homeostasis GO:0050891 9.37 AQP1 AVP
7 serotonin receptor signaling pathway GO:0007210 9.32 HTR1A HTR3A
8 hyperosmotic salinity response GO:0042538 9.26 AQP1 AVP
9 positive regulation of saliva secretion GO:0046878 9.16 AQP1 TAC1
10 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 8.96 HTR1A HTR7
11 vasoconstriction GO:0042310 8.8 AVP HTR1A HTR7

Molecular functions related to Motion Sickness according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.16 HTR1A HTR7
2 G-protein coupled serotonin receptor activity GO:0004993 9.13 HTR1A HTR3A HTR7
3 serotonin binding GO:0051378 8.8 HTR1A HTR3A HTR7

Sources for Motion Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....